goat polyclonal anti her3  (R&D Systems)

Journal: Oncology Letters

Article Title: Soluble HER3 predicts survival in bladder cancer patients

doi: 10.3892/ol.2017.7470

Figure Lengend Snippet: Calibration curve for capture and detection antibodies used in sHER3 ELISA. Calibration curve for sHER3 ELISA using (A) conditioned medium from WM266 melanoma cells or (B) recombinant HER3 as the calibrator. (C) Western blotting with capture (catalogue no. MAB3481) and detection (catalogue no. AF234) antibodies, showing full-length HER3 (180 kDa) in cell lysates (lanes 1 and 3) and sHER3 (~85 kDa) in conditioned media (lanes 2 and 4). A 45 kDa band was also detected with capture antibody, but not with detection antibody. Two cell lines, DU145 (lanes 1 and 2) and WM266 (lanes 3 and 4), were used. sHER3, soluble human epidermal growth factor receptor.

Article Snippet: A sandwich ELISA was developed employing monoclonal anti-human HER3 antibody (dilution, 1:1,000; catalogue no. MAB3481; R&D Systems Europe, Ltd., Abingdon, UK) as the capture antibody and the polyclonal goat anti-human HER3 antibody (dilution, 1:200; catalogue no. AF234; R&D Systems Europe, Ltd.) as the detection antibody.

Techniques: Enzyme-linked Immunosorbent Assay, Recombinant, Western Blot

Journal: Oncology Letters

Article Title: Soluble HER3 predicts survival in bladder cancer patients

doi: 10.3892/ol.2017.7470

Figure Lengend Snippet: Effects of sHER3 on HER3 signalling, proliferation and migration of HCV-29 bladder cancer cells. (A) Western blotting analysis of p-HER3 (180 kDa) and t-HER3 (180 kDa) levels in HCV-29 cells treated with recombinant sHER3 peptide at the indicated concentrations: 0 (untreated control) 10 and 20 nM for 24 h. (B) xCELLigence data presenting the growth effect of recombinant sHER3 peptide on HCV-29 cells. Differences in cell density were normalised for at 0 h (the time of treatment, vertical black line). Significant differences (P<0.05) in cell proliferation were identified thorough-out, at and after 24 h treatment between cells treated with 20 nM sHER3 peptide compared with untreated cells. ***Denotes difference in control and treated cells at 96 h (P=0.0005), *denotes P<0.05. Data represent the mean ± standard error of the mean following three replicates. (C) xCELLigence data presenting the migration of HCV-29 cells at 24 h after HER3 treatment at the indicated concentrations, data represent the mean ± standard error of the mean following four replicates. Analysis of significance for overall group differences was performed by the Kruskal-Wallis test (P=0.0016). The multiple comparisons' criterion was employed to identify differences between groups and is indicated as *P<0.05 and **P<0.005. sHER3, soluble human epidermal growth factor receptor; p, phosphorylated; t, total

Article Snippet: A sandwich ELISA was developed employing monoclonal anti-human HER3 antibody (dilution, 1:1,000; catalogue no. MAB3481; R&D Systems Europe, Ltd., Abingdon, UK) as the capture antibody and the polyclonal goat anti-human HER3 antibody (dilution, 1:200; catalogue no. AF234; R&D Systems Europe, Ltd.) as the detection antibody.

Techniques: Migration, Western Blot, Recombinant, Control